Recursion Pharmaceuticals combines artificial intelligence, automation, and biotechnology research across multiple ...
Hosted on MSN
Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 2026
CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...
Clinical-stage biotechnology firm Recursion announced the release of an open-source biological dataset, RxRx1, which the company has been building for more than five years. The dataset is composed of ...
On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
Recursion has rapidly established itself as a leader in the field of AI-enabled biotechnology. The company's BioHive-2 supercomputer, powered by Nvidia AI chips, is one of the world's most powerful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results